Global Thorium-228 Market Growth 2025-2031
Description
The global Thorium-228 market size is predicted to grow from US$ 2.2 million in 2025 to US$ 3.2 million in 2031; it is expected to grow at a CAGR of 6.7% from 2025 to 2031.
Thorium-228 is a radioactive isotope. In irradiated thorium elements, 228Th can be produced through specific nuclear reactions. For example, when radium-226 is irradiated in the High Flux Isotope Reactor, actinium-227 and thorium-228 are produced. As a byproduct of the production of actinium-227, thorium-228 can be produced in large quantities.
Thorium-228 has a wide range of applications in the medical field. It can be used to make radium-224/lead-212 generators, which allow radium-224 extracted from thorium-228 to decay over time and produce lead-212 and bismuth-212. Lead-212 and bismuth-212 can be used to study targeted alpha therapies to attack metastatic skin cancer and neuroendocrine tumors with minimal damage to surrounding tissues. In addition, thorium-228 can be combined with other biomolecules to develop a cancer targeted therapy combination. In addition to medical applications, thorium-228 may have other potential applications. However, due to its radioactivity and decay characteristics, these applications need to be carefully evaluated and strictly managed.
Due to the strong radioactivity of thorium-228, thorium separated from irradiated thorium is best stored for 10 to 20 years before reuse to ensure that its radioactivity level is reduced to a safe range. When storing and handling thorium-228, strict radiation protection measures need to be taken to avoid health hazards caused by ionizing radiation.
As a radioactive isotope, thorium 228 has potential application value in many fields, and its development is jointly affected by multiple driving factors and hindering factors.
Thorium 228 has broad application prospects in the medical field, especially in cancer treatment. It can be used to make radium-224/lead-212 generators, and the lead-212 and bismuth-212 produced by these generators can be used to study targeted alpha therapy, which has therapeutic effects on cancers such as metastatic skin cancer and neuroendocrine tumors. With the rising incidence of cancer and the increasing demand for cancer treatment, the demand for thorium 228 is expected to continue to grow.
Continuous technological innovation provides more possibilities for the extraction, separation and application of thorium 228. For example, by improving nuclear reaction technology, the production efficiency and purity of thorium 228 can be improved; by developing new radioisotope labeling technology, thorium 228 can be combined with other biomolecules to develop more cancer targeted therapy combinations.
Governments of various countries have given certain policy support to the research and application of radioisotopes. These policies include financial support, tax incentives, R&D subsidies, etc., which provide a good policy environment for the R&D and application of thorium 228.
There are many technical difficulties in the extraction, separation and application of thorium 228. For example, how to efficiently extract and separate thorium 228, how to ensure its safety and stability, and how to apply it in the medical field all require further technical research and innovation. The production and application costs of thorium 228 are high. This includes raw material costs, production costs, R&D costs, and operating costs. The high cost limits the widespread application and commercialization of thorium 228.
LP Information, Inc. (LPI) ' newest research report, the “Thorium-228 Industry Forecast” looks at past sales and reviews total world Thorium-228 sales in 2024, providing a comprehensive analysis by region and market sector of projected Thorium-228 sales for 2025 through 2031. With Thorium-228 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Thorium-228 industry.
This Insight Report provides a comprehensive analysis of the global Thorium-228 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Thorium-228 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Thorium-228 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Thorium-228 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Thorium-228.
This report presents a comprehensive overview, market shares, and growth opportunities of Thorium-228 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
99.0%-99.5%
＞99.5%
Segmentation by Application:
Nuclear Medicine
Scientific Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ORNL(NIDC)
Eckert & Ziegler
Laboratoire Maurice Tubiana
Thor Medicals
RITVERC JSC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Thorium-228 market?
What factors are driving Thorium-228 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Thorium-228 market opportunities vary by end market size?
How does Thorium-228 break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Thorium-228 is a radioactive isotope. In irradiated thorium elements, 228Th can be produced through specific nuclear reactions. For example, when radium-226 is irradiated in the High Flux Isotope Reactor, actinium-227 and thorium-228 are produced. As a byproduct of the production of actinium-227, thorium-228 can be produced in large quantities.
Thorium-228 has a wide range of applications in the medical field. It can be used to make radium-224/lead-212 generators, which allow radium-224 extracted from thorium-228 to decay over time and produce lead-212 and bismuth-212. Lead-212 and bismuth-212 can be used to study targeted alpha therapies to attack metastatic skin cancer and neuroendocrine tumors with minimal damage to surrounding tissues. In addition, thorium-228 can be combined with other biomolecules to develop a cancer targeted therapy combination. In addition to medical applications, thorium-228 may have other potential applications. However, due to its radioactivity and decay characteristics, these applications need to be carefully evaluated and strictly managed.
Due to the strong radioactivity of thorium-228, thorium separated from irradiated thorium is best stored for 10 to 20 years before reuse to ensure that its radioactivity level is reduced to a safe range. When storing and handling thorium-228, strict radiation protection measures need to be taken to avoid health hazards caused by ionizing radiation.
As a radioactive isotope, thorium 228 has potential application value in many fields, and its development is jointly affected by multiple driving factors and hindering factors.
Thorium 228 has broad application prospects in the medical field, especially in cancer treatment. It can be used to make radium-224/lead-212 generators, and the lead-212 and bismuth-212 produced by these generators can be used to study targeted alpha therapy, which has therapeutic effects on cancers such as metastatic skin cancer and neuroendocrine tumors. With the rising incidence of cancer and the increasing demand for cancer treatment, the demand for thorium 228 is expected to continue to grow.
Continuous technological innovation provides more possibilities for the extraction, separation and application of thorium 228. For example, by improving nuclear reaction technology, the production efficiency and purity of thorium 228 can be improved; by developing new radioisotope labeling technology, thorium 228 can be combined with other biomolecules to develop more cancer targeted therapy combinations.
Governments of various countries have given certain policy support to the research and application of radioisotopes. These policies include financial support, tax incentives, R&D subsidies, etc., which provide a good policy environment for the R&D and application of thorium 228.
There are many technical difficulties in the extraction, separation and application of thorium 228. For example, how to efficiently extract and separate thorium 228, how to ensure its safety and stability, and how to apply it in the medical field all require further technical research and innovation. The production and application costs of thorium 228 are high. This includes raw material costs, production costs, R&D costs, and operating costs. The high cost limits the widespread application and commercialization of thorium 228.
LP Information, Inc. (LPI) ' newest research report, the “Thorium-228 Industry Forecast” looks at past sales and reviews total world Thorium-228 sales in 2024, providing a comprehensive analysis by region and market sector of projected Thorium-228 sales for 2025 through 2031. With Thorium-228 sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Thorium-228 industry.
This Insight Report provides a comprehensive analysis of the global Thorium-228 landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Thorium-228 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Thorium-228 market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Thorium-228 and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Thorium-228.
This report presents a comprehensive overview, market shares, and growth opportunities of Thorium-228 market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
99.0%-99.5%
＞99.5%
Segmentation by Application:
Nuclear Medicine
Scientific Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ORNL(NIDC)
Eckert & Ziegler
Laboratoire Maurice Tubiana
Thor Medicals
RITVERC JSC
Key Questions Addressed in this Report
What is the 10-year outlook for the global Thorium-228 market?
What factors are driving Thorium-228 market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Thorium-228 market opportunities vary by end market size?
How does Thorium-228 break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
80 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Thorium-228 by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Thorium-228 by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
